192 related articles for article (PubMed ID: 29579058)
1. Comparative oncology approach to drug repurposing in osteosarcoma.
Parrales A; McDonald P; Ottomeyer M; Roy A; Shoenen FJ; Broward M; Bruns T; Thamm DH; Weir SJ; Neville KA; Iwakuma T; Fulbright JM
PLoS One; 2018; 13(3):e0194224. PubMed ID: 29579058
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis.
Murahari S; Jalkanen AL; Kulp SK; Chen CS; Modiano JF; London CA; Kisseberth WC
BMC Cancer; 2017 Jan; 17(1):67. PubMed ID: 28109246
[TBL] [Abstract][Full Text] [Related]
3. STAT3 inhibitor, cucurbitacin I, is a novel therapeutic agent for osteosarcoma.
Oi T; Asanuma K; Matsumine A; Matsubara T; Nakamura T; Iino T; Asanuma Y; Goto M; Okuno K; Kakimoto T; Yada Y; Sudo A
Int J Oncol; 2016 Dec; 49(6):2275-2284. PubMed ID: 27840900
[TBL] [Abstract][Full Text] [Related]
4. Effects of aurothiomalate treatment on canine osteosarcoma in a murine xenograft model.
Scharf VF; Farese JP; Siemann DW; Abbott JR; Kiupel M; Salute ME; Milner RJ
Anticancer Drugs; 2014 Mar; 25(3):332-9. PubMed ID: 24304691
[TBL] [Abstract][Full Text] [Related]
5. Proteasome Inhibitor MG132 Enhances Cisplatin-Induced Apoptosis in Osteosarcoma Cells and Inhibits Tumor Growth.
Sun F; Zhang Y; Xu L; Li S; Chen X; Zhang L; Wu Y; Li J
Oncol Res; 2018 May; 26(4):655-664. PubMed ID: 29191257
[TBL] [Abstract][Full Text] [Related]
6. The Anthelmintic Drug Niclosamide Inhibits the Proliferative Activity of Human Osteosarcoma Cells by Targeting Multiple Signal Pathways.
Liao Z; Nan G; Yan Z; Zeng L; Deng Y; Ye J; Zhang Z; Qiao M; Li R; Denduluri S; Wang J; Wei Q; Geng N; Zhao L; Lu S; Wang X; Zhou G; Luu HH; Haydon RC; He TC; Wang Z
Curr Cancer Drug Targets; 2015; 15(8):726-38. PubMed ID: 26118906
[TBL] [Abstract][Full Text] [Related]
7. A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy.
Sidarovich V; De Mariano M; Aveic S; Pancher M; Adami V; Gatto P; Pizzini S; Pasini L; Croce M; Parodi F; Cimmino F; Avitabile M; Emionite L; Cilli M; Ferrini S; Pagano A; Capasso M; Quattrone A; Tonini GP; Longo L
Mol Cancer Ther; 2018 Jul; 17(7):1405-1415. PubMed ID: 29695637
[TBL] [Abstract][Full Text] [Related]
8. Combinatorial screening using orthotopic patient derived xenograft-expanded early phase cultures of osteosarcoma identify novel therapeutic drug combinations.
Loh AHP; Stewart E; Bradley CL; Chen X; Daryani V; Stewart CF; Calabrese C; Funk A; Miller G; Karlstrom A; Krafcik F; Goshorn DR; Vogel P; Bahrami A; Shelat A; Dyer MA
Cancer Lett; 2019 Feb; 442():262-270. PubMed ID: 30395907
[TBL] [Abstract][Full Text] [Related]
9. Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin.
Karsa M; Kosciolek A; Bongers A; Mariana A; Failes T; Gifford AJ; Kees UR; Cheung LC; Kotecha RS; Arndt GM; Haber M; Norris MD; Sutton R; Lock RB; Henderson MJ; Somers K
Br J Cancer; 2021 Jul; 125(1):55-64. PubMed ID: 33837299
[TBL] [Abstract][Full Text] [Related]
10. Caffeine citrate enhanced cisplatin antitumor effects in osteosarcoma and fibrosarcoma in vitro and in vivo.
Abe K; Yamamoto N; Hayashi K; Takeuchi A; Tsuchiya H
BMC Cancer; 2019 Jul; 19(1):689. PubMed ID: 31307409
[TBL] [Abstract][Full Text] [Related]
11. The Thioredoxin Reductase Inhibitor Auranofin Suppresses Pulmonary Metastasis of Osteosarcoma, But Not Local Progression.
Kinoshita H; Shimozato O; Ishii T; Kamoda H; Hagiwara Y; Tsukanishi T; Ohtori S; Yonemoto T
Anticancer Res; 2021 Oct; 41(10):4947-4955. PubMed ID: 34593442
[TBL] [Abstract][Full Text] [Related]
12. Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications.
Liu W; Stachura P; Xu HC; Umesh Ganesh N; Cox F; Wang R; Lang KS; Gopalakrishnan J; Häussinger D; Homey B; Lang PA; Pandyra AA
J Exp Clin Cancer Res; 2020 Feb; 39(1):38. PubMed ID: 32085796
[TBL] [Abstract][Full Text] [Related]
13. Capsaicin inhibits proliferation and induces apoptosis in osteosarcoma cell lines via the mitogen‑activated protein kinase pathway.
Zhang Y; Deng X; Lei T; Yu C; Wang Y; Zhao G; Luo X; Tang K; Quan Z; Jiang D
Oncol Rep; 2017 Nov; 38(5):2685-2696. PubMed ID: 29048662
[TBL] [Abstract][Full Text] [Related]
14. Tranilast enhances the effect of anticancer agents in osteosarcoma.
Nakashima T; Nagano S; Setoguchi T; Sasaki H; Saitoh Y; Maeda S; Komiya S; Taniguchi N
Oncol Rep; 2019 Jul; 42(1):176-188. PubMed ID: 31059083
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Testing of a Novel Niclosamide Stearate Prodrug Therapeutic (NSPT) Shows Efficacy Against Osteosarcoma.
Reddy GB; Kerr DL; Spasojevic I; Tovmasyan A; Hsu DS; Brigman BE; Somarelli JA; Needham D; Eward WC
Mol Cancer Ther; 2020 Jul; 19(7):1448-1461. PubMed ID: 32371588
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of nuclear factor-κB by dehydroxymethylepoxyquinomicin induces schedule-dependent chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells.
Castro-Gamero AM; Borges KS; da Silva Silveira V; Lira RC; de Paula Gomes Queiroz R; Valera FC; Scrideli CA; Umezawa K; Tone LG
Anticancer Drugs; 2012 Jul; 23(6):638-50. PubMed ID: 22382389
[TBL] [Abstract][Full Text] [Related]
17. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
[TBL] [Abstract][Full Text] [Related]
18. In vitro antineoplastic effects of auranofin in canine lymphoma cells.
Zhang H; Rose BJ; Pyuen AA; Thamm DH
BMC Cancer; 2018 May; 18(1):522. PubMed ID: 29724201
[TBL] [Abstract][Full Text] [Related]
19. Auranofin is a potent suppressor of osteosarcoma metastasis.
Topkas E; Cai N; Cumming A; Hazar-Rethinam M; Gannon OM; Burgess M; Saunders NA; Endo-Munoz L
Oncotarget; 2016 Jan; 7(1):831-44. PubMed ID: 26573231
[TBL] [Abstract][Full Text] [Related]
20. YM155 enhances the cytotoxic activity of etoposide against canine osteosarcoma cells.
Ong SM; Saeki K; Kok MK; Nakagawa T; Nishimura R
J Vet Med Sci; 2019 Aug; 81(8):1182-1190. PubMed ID: 31308291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
